We have evaluated the durability of engraftment and the potential of remobilization in mice reconstituted with mobilized peripheral blood progenitor cells (PBPC). Female mice which had been reconstituted with cytokine-mobilized PBPC from male donors were serially transplanted into second, third, fourth and fifth lethally irradiated female recipients at intervals of 6-10 months. Male-derived hematopoiesis was determined in recipient mice at each serial transplantation. Male-positive CFCs were detected after 5 passages for 45 months, but declined from Ͼ95% at passage 1 to 74% at passage 2, 33% at passage 4, and 28% at passage 5. Long-term survival also declined from 97% at passage 2 to 53% at passage 4, and 27% at passage 5. The results demonstrated that mobilized PBPC were able to provide engraftment for more than 45 months, but the engraftment provided by mobilized PBPC decreased at each serial passage. In addition, mice reconstituted with mobilized PBPC (at 1 year post transplantation) were treated with the same cytokines as in the primary mobilization (remobilization). The remobilized PBPC were harvested and transplanted into lethally irradiated secondary recipients. Male-derived CFCs were evaluated at 20 months post transplantation. Mice transplanted with PBPC remobilized with rhG-CSF or rhG-CSF plus rrSCF-PEG showed 70% and 89% male-positive CFCs respectively, demonstrating that mice reconstituted with mobilized PBPC could be remobilized and that the remobilized PBPC were also capable of providing longterm hematopoietic reconstitution. Our studies demonstrated that mobilized PBPC have extensive proliferative or self-renewal capacity to provide durable engraftment and that marrow repopulating cells in PBPC reconstituted mice can be remobilized, suggesting that patients who relapse after PBPC transplantation may be remobilized for a second transplantation to support additional chemotherapy.
Adult bone marrow (BM) contains a hierarchy of cells including the hematopoietic stem cells (HSC, or long-term reconstituting cells), hematopoietic precursors at different stages of differentiation, and mature hematopoietic cells. Although a small number of hematopoietic precursors are present in the peripheral blood (PB), most hematopoietic precursors reside in the BM.
1-3 BM hematopoietic precursors can be shifted to the PB and extramedullary sites (mobilization) in response to cytotoxic drugs, cytokines, or their combination (review, see Ref. 4) . Mobilized PBPC have been widely used to support high-dose chemotherapy or chemoradiotherapy for hematological malignancies, such as leukemias and lymphomas; and for solid tumors, such as breast cancer, because of their capacity for rapid hematopoietic reconstitution compared with conventional bone marrow transplantation (BMT). 5, 6 One major issue of PBPC transplantation is whether the mobilized PBPC have the same capacity to provide durable long-term engraftment equivalent to BM cells. A number of studies have demonstrated that mobilized PBPC are able to provide long-term (more than 6 months) engraftment in animals. 7, 8 Whether the engraftment provided by mobilized PBPC is as durable as in recipients transplanted with normal BM cells remains to be demonstrated in both animal models and human settings. A second related issue with PBPC transplantation is that a significant proportion of patients relapse after PBPC transplantation. It is not known whether these patients can be remobilized, subjected to a second cytokine administration and PBPC harvest, to support additional chemotherapy treatment. The main aim of this study was to test the durability of engraftment provided by mobilized PBPC and to evaluate whether mice reconstituted with mobilized PBPC could be remobilized.
Hematopoietic reconstituting capacity of BM cells can be serially passaged in animals. [9] [10] [11] [12] However, the reconstituting capacity of BM cells is diminished during serial transplantation and is eventually exhausted. 13 We hypothesized that if mobilized PBPC have the same, or equivalent, long-term engraftment potential to BM cells, BM cells from mice transplanted with mobilized PBPC would be able to be serially transplanted in lethally irradiated recipients. In addition, animals reconstituted with mobilized PBPC might be able to be remobilized. That is, in response to a second cytokine treatment, the hematopoietic precursors could be mobilized to the PB again, and such remobilized PBPC would also have long-term reconstituting capacity. Therefore, we established mice reconstituted in the long-term with PBPC mobilized by either recombinant human granulocyte colony-stimulating factor (rhG-CSF) alone or rhG-CSF plus pegylated recombinant rat stem cell factor (rrSCF-PEG). We and others demonstrated that PBPC mobilized by rhG-CSF or rhG-CSF plus rrSCF-PEG were able to provide rapid short-term and long-term engraftment in lethally irradiated mice, demonstrating the presence of long-term hematopoietic reconstituting cells in the mobilized PBPC. 7, 8 In addition, we showed that PBPC mobilized by rhG-CSF plus rrSCF-PEG contained a higher number of cells capable of providing long-term engraftment than PBPC mobilized by rhG-CSF alone. 8, 14 In the current report, we further examined the engraftment potential of PBPC in the extreme case of serial transplantation of PBPC mobilized by rhG-CSF plus rrSCF-PEG in lethally irradiated recipients for more than 45 months. In addition, we explored the possibility of remobilizing PBPC in mice which had been previously transplanted with mobilized PBPC.
Materials and methods

Mice
Eight-to 12-week-old male splenectomized and female (C57BL/6J × DBA/2J) F 1 (BDF 1 ) mice were purchased from Charles River Laboratories (Wilmington, MA, USA). All animals were housed under pathogen-free conditions and were supplied with acidified water post transplantation.
Mobilization
Mobilization of PBPC using BDF 1 mice has been described previously. 8, 15 Briefly, male splenectomized BDF 1 mice were treated with rhG-CSF at 200 g/kg/day, or rhG-CSF 200 g/kg/day plus rrSCF-PEG at 25 g/kg/day for 7 days. Growth factors were administered daily by intravenous injection. Both rhG-CSF and rrSCF-PEG were produced by Amgen (Thousand Oaks, CA, USA). PB was harvested by cardiac puncture and collected into EDTA-containing tubes and analyzed on a Technicon H1E blood analyzer (Miles, Tarrytown, NY, USA). Low density (LD) cells (Ͻ1.080 g/ml) which contain most of the long-term reconstituting activities, 16 were obtained by layering PB on Nycodenz density gradients (Accurate Chemical and Scientific Corp, Westbury, NY), spun at 2000 g, 20 min washed with PBS, and re-suspended in isotonic saline containing 1% bovine serum albumin (BSA). The low density cells were transplanted into ␥-irradiated (Cs 137 , 2 × 6.0 Gy, split dose 4 h apart) female BDF 1 recipients.
Serial transplantation
Female mice reconstituted with male PBPC mobilized with rhG-CSF plus rrSCF-PEG were used as donors in serial transplantation experiments. BM cells harvested from two femurs plus two tibias of individual animals were transplanted into three lethally irradiated (Cs 137 , 2 × 6.0 Gy, split dose 4 h apart) female recipients. Each recipient received donor BM cells of approximately one femur equivalent. At intervals of 6-10 months post transplantation, BM cells were consecutively transplanted into lethally irradiated second, third, fourth and fifth female recipients.
Remobilization
Female mice transplanted with mobilized PBPC containing Ͼ95% donor (male cells) were splenectomized at 9 months and remobilized at 14 months post transplantation. Splenectomy results in an increased number of progenitor cells in PB. Mice which had been transplanted with PBPC mobilized with rhG-CSF were treated with rhG-CSF (200 g/kg/day). Mice which had been transplanted with PBPC mobilized with rhG-CSF plus rrSCF-PEG were treated with the same factors at the above doses. Growth factors were administered daily by intravenous injection for 5 days. PB was harvested and analyzed as described above. LD cells were isolated and transplanted into ␥-irradiated (Cs 137 , 2 × 6.0 Gy, split dose 4 h apart) female BDF 1 recipients. Each recipient mouse received 1 × 10 6 LD cells.
Colony-forming cell (CFC) assay.
Nucleated bone marrow cells (2 × 10 4 ) were plated in 1.0 ml IMDM plus methyl cellulose containing 10% fetal bovine serum (FBS), 1% BSA, lipids, transferrin, insulin, 17 2.5 ng/ml rmIL-3, 2.5 ng/ml rhIL-1␤, 100 ng/ml rrSCF, 100 ng/ml rhIL-6, 100 ng/ml rhIL-11, 100 ng/ml rhTPO and 1 Unit/ml rhEpo. All recombinant factors were supplied by Amgen. Granulocyte/macrophage (GM) and multilineage colonies (CFCmulti) were scored after 9 days incubation in 5% CO 2 at 37°C.
Y-chromosome polymerase chain reaction (PCR) analysis
PCR analysis of male-derived hematopoiesis in whole blood and single colonies has been described in detail previously. 8 Briefly, processed DNA samples were amplified in a 50 l reaction containing 10 pmols of mouse Y chromosome-specific primers, or mouse PDGF B receptor-specific primers, 1.5 mm MgCl 2 , 50 mm KCl, 10 mm TrisHCl, pH 8.3, 0.2 mm dNTPs, and 2.5 unit Taq polymerase (Boehringer Mannheim, Indianapolis, IN, USA). PCR reaction was initiated at 94°C for 4 min, followed by 30 to 35 cycles at 94°C for 15 s, 62°C for 30 s, and 72°C for 1 min. Amplification with Y-specific primers results in a 722 bp fragment corresponding to the Sry locus sequence 256-978. 18 Amplification with PDGF B receptor primers generates a fragment of approximately 750 bp corresponding to mouse PDGF B receptor cDNA sequence 948-1166, which contains an intron sequence. 19 Each PCR amplification included a male (positive) and a female (negative) control. Amplified products were confirmed by Southern analysis hybridizing with internal oligoes of Sry and PDGF B receptor sequences, respectively.
The statistical analysis was performed by the generalized linear model using a Poisson link function by two-sided ttest pairwise comparisons (SAS/STAT software, release 6.11; SAS Institute Cary, NC, USA). An overview of the transplantation experiments is outlined in Figure 1 . 
Results
The initial mobilization of PBPC was performed with either rhG-CSF, or rhG-CSF plus rrSCF-PEG. Although PBPC mobilized with both treatments were capable of providing long-term donor engraftment in lethally irradiated recipients, PBPC mobilized with the combination of rhG-CSF and rrSCF-PEG had a higher percentage of male-derived hematopoiesis compared to PBPC mobilized with rhG-CSF alone. 8 Therefore, mice reconstituted with PBPC mobilized with rhG-CSF plus rrSCF-PEG were used as donors for serial transplantation. No selection of male-positive donors was made at each round of serial transplantation, except for the fifth transplantation in which only male-positive mice, determined by whole blood PCR analysis, were used as donors.
Results from the serial transplantation are summarized in Table 1 . The long-term survival of the serially transplanted mice declined gradually from 97% at the second transplantation to 27% at the fifth transplantation, although all the recipient mice received 8-10 × 10 6 nucleated BM cells. The 70% long-term survival of primary PBPC transplanted recipients was due to the low number of transplanted LD cells (2.5 × 10 5 LD per mouse). When 1 × 10 6 LD cells were transplanted, 100% long-term (Ͼ6 months) survival was achieved in these animals. 8 Male-derived hematopoiesis was evaluated at each transplantation by PCR analysis of a Y-chromosome specific DNA sequence in whole blood and CFCs in the BM. The whole blood PCR analysis was performed 1-2 weeks prior to transplantation and was able to detect Ͼ2-5% male-positive cells in the PB. All the long-term surviving mice from the first to the third transplantation were male-positive determined by whole blood PCR analysis (Table 1) . However, the whole blood PCR analysis did not quantitate male engraftment due to the variations of PCR amplification. Thus, we performed single-colony PCR analysis to assess male engraftment in the serial transplanted mice. BM cultures were initiated by sparsely seeding 1-2 × 10 4 cells/ml in methylcellulose. Macroscopic colonies containing approximately Ͼ1 × 10 4 cells were individually picked and processed. Morphological staining was performed on the picked colonies, showing that 10-20% colonies were multilineage (more then three myeloid lineages), and 80-90% were granulocyte/ Table shows five generations of serial transplantation experiments. The first transplantation started with 2.5 × 10 5 low-density cells from mobilized male mice. Long-term survival shows the survival of animals at the end of each transplantation. Male-derived CFC were determined by single-colony PCR. Eight to 12 single colonies from each animal were picked at day 9-11 from methylcellulose cultures of BM cells. Each sample was processed and amplified with Y+ specific primers and PDGF BR-specific primers. 'n' indicates the number of transplanted animals; ND = not determined; Ȱ indicates the comparison between 2nd and 4th transplantation. P value was calculated by two-sided t-test. macrophage colonies. DNA sequences from single colonies were amplified with Y-specific primers and PDGF B receptor-specific primers, which acted as an internal control for PCR amplification. Table 1 shows that 98 and 74% malepositive CFCs were detected in the primary and secondary recipients, respectively. However, male-positive CFCs declined to 33 and 28% at fourth and fifth recipients, respectively. The decline of male-positive CFCs was statistically significant at each passage, except for the fifth transplantation. These results demonstrated that PBPC mobilized by rhG-CSF plus rrSCF-PEG were able to support hematopoiesis in the serial transplantation experiments for more than 45 months, but reconstituting capacity sharply declined at the fourth and fifth transplantations.
Remobilization of mice that had been previously transplanted with mobilized PBPC was evaluated by the levels of WBC, and CFCs in the remobilized PB ( Table 2 ). Both factor-treated groups had elevated WBC levels compared with carrier-treated mice. The levels of CFCmulti and GM-CFC in the carrier-treated group were barely detectable, while rhG-CSF-and rhG-CSF plus rrSCF-PEG-treated group had 10-and 48-fold higher numbers of GM-CFC compared with the carrier-treated group, respectively. In addition, remobilization of mice that were reconstituted with rhG-CSF-mobilized PBPC with rhG-CSF resulted in a moderate increase of WBC and CFCs in the PB ( Table  2 ). Remobilization of mice that were reconstituted with rhG-CSF plus rrSCF-PEG-mobilized PBPC with the same factor combination resulted in a more efficient mobilization, demonstrated by 2.6-, 2.4-and 4.3-fold higher WBC, CFCmulti, and GM-CFC in the PB than rhG-CSF-treated group, respectively. This is consistent with the synergistic effect of rhG-CSF plus rrSCF-PEG compared with rhG-CSF which had been demonstrated in previous studies. 7, 8 Long-term survival of secondary recipients that received remobilized PBPC is shown in Figure 2 . Mice transplanted with rhG-CSF plus rrSCF-PEG remobilized PBPC (group B) had higher long-term survival compared with those transplanted with rhG-CSF alone remobilized PBPC (group A). These data are also consistent with the effects of rhG-CSF plus rrSCF-PEG mobilized PBPC in primary mobilization.
14 Most long-term surviving animals were male-positive as determined by whole blood PCR analysis. Singlecolony PCR analysis, performed at 20 months post trans- Table 2 Remobilization of mice previously transplanted with mobilized PBPC plantation, showed that 70%, and 89% of CFCs were malederived in the rhG-CSF-and rhG-CSF plus rrSCF-PEGtreated group, respectively (Table 3 ). Mice remobilized with rhG-CSF plus rrSCF-PEG had significantly higher percentage of male-positive CFCs. These results demonstrate Table 3 Male-derived hematopoiesis in mice reconstituted with remobilized PBPC Male-derived hematopoiesis was determined by PCR analysis of Y chromosomal-specific sequence in whole blood and marrow CFCs. Mice were sacrificed at 20 months post transplantation. Male-derived CFCs were determined in the same way as described in Table 1 . P value was calculated by two-sided t-test.
that the long-term reconstituting cells in mice reconstituted with mobilized PBPC can be remobilized to provide further hematopoietic reconstitution in secondary irradiated recipients.
Discussion
Mobilized PBPC have been used in autologous and allogeneic BM transplantation settings because of their rapid engraftment compared with conventional BM transplantation (review see Refs 4 and 5 Odgen and Micklem et al 12 and others. 10, 11 These authors demonstrated that marrow repopulating activities could be serially transplanted in either irradiated recipients, or W mutant mice, for three to five passages. The repopulating capacity of the serially transplanted BM cells eventually failed to further reconstitute hematopoietic system. 13 As expected, the long-term repopulating potential of mobilized PBPC diminished in the process of serial transplantation.
In the first 2 years of the serial transplantation, the longterm reconstituting stem cells must have undergone extensive proliferation and differentiation to provide 98% and 74% male-derived CFC in the primary and secondary recipients, respectively, when only 2.5 × 10 5 LD cells (equivalent to 20 l mobilized PB) initially were trans-planted. In the second 2 years of serial transplantation, the long-term reconstituting cells appeared to have exhausted the potential of further proliferation and differentiation. Such decreased reconstituting capacity eventually failed to compete efficiently with female hematopoietic cells derived from endogenous, and from previous donor marrow. The actual percentage of male-positive CFCs might even be overestimated at fourth and fifth transplantation, since the origin of hematopoietic cells was not evaluated in the dead animals. Therefore, the long-term surviving animals might reflect a selection of male-engraftment in these recipients. The presence of male-derived CFCs indicated that some mobilized long-term reconstituting cells had more than 4 years life span (some of the fifth recipients are still alive at 12 months post transplantation). It is not known what triggered the long-term reconstituting cells to cease further proliferation, or self-renewal. Nevertheless, our studies demonstrated that the long-term reconstituting capacity of mobilized PBPC could be serially transplanted in the lethally irradiated recipients for five generations and for more than 4 years.
We further demonstrated that hematopoietic precursors in mice reconstituted with mobilized PBPC could be remobilized, and the remobilized PBPC were also able to provide long-term male-derived hematopoiesis in the secondary recipients. These results suggest that patients who relapse after PBPC transplantation may be remobilized for a second transplantation to support additional chemotherapy. The efficiency of remobilization may depend on the number of available hematopoietic stem cells. We observed that the percentage of male-derived CFCs in mice reconstituted with remobilized PBPC was lower compared with mice reconstituted with primary mobilized PBPC, even though four times more LD cells were transplanted (Table 4) . Such a decrease could be due to the total number of long-term reconstituting cells in the recipients which initially received 2 × 10 5 LD cells, being lower than that in normal animals, resulting in fewer long-term reconstituting cells available to be remobilized. Consistent with our observations in primary mobilization, 8, 15 the combination of rhG-CSF plus rrSCF-PEG resulted in higher levels of WBC, CFCs in the remobilized PB, and a higher percentage of male-positive CFCs in the long-term survivors compared with rhG-CSF alone, although the results of remobilization reflected both primary and secondary mobilizations. In the primary mobilization, we observed a significant difference in male-positive CFCs between rhG-CSF-and rhG-CSF plus rrSCF-PEG-mobilized animals. 8, 14 However, in the remobilization, the effects of addition of rrSCF-PEG were seen in the levels of WBC, and CFCs in the remobilized PB, but not in the percentage of male-positive CFCs in the long-term survivors (data not shown), suggesting that fewer long-term reconstituting cells were present to be remobilized compared with normal BM in the primary mobilization.
Whether the mobilized PB hematopoietic stem cells are the same as BM stem cells remains to be determined. The definitive answer to this question may rely on phenotypic characterization of the two cell populations in vitro, and functional demonstration of their ability to reconstitute and maintain long-term hematopoiesis in vivo. It is unclear what triggers the shift of hematopoietic precursors including long-term reconstituting stem cells from BM to PB and extramedullary sites in response to cytokine stimulation. The mobilization of PBPC appears to be a reversible process, since both the mobilized precursors in the PB and precursors in the BM returned to normal levels after withdrawal of cytokine treatment. 20, 21 Recently, it has been demonstrated that the mobilized PBPC have different physical properties including c-kit expression, 22 adhesion molecules, 23, 24 radiosensitivities, 25 and gene transduction efficiency compared with their normal BM counterparts. 26 These observations suggest that long-term reconstituting cells in the mobilized PBPC physically differ from their counterparts in normal BM. However, our results demonstrated that the intrinsic hematopoietic reconstituting capacity of mobilized long-term reconstituting cells was preserved during mobilization, suggesting that the mobilized PBPC are functionally equivalent to normal BM cells.
